Current management of postherpetic neuralgia

Neurologist

Volumn 8, Issue 6, 2002, Pages 339-350

  Panlilio, Louis M ^a   Christo, Paul J ^a   Raja, Srinivasa N ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Herpes zoster; Neuropathic pain; Postherpetic neuralgia; Treatment

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; DICLOFENAC; FAMCICLOVIR; FOSCARNET; GABAPENTIN; LIDOCAINE; METHYLPREDNISOLONE; OPIATE AGONIST; OXYCODONE; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; VALACICLOVIR;

ALGORITHM; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; DORSAL ROOT; GANGLION; HERPES ZOSTER; HUMAN; HYPERALGESIA; INTRACTABLE PAIN; PATHOPHYSIOLOGY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN DISEASE; SYMPTOM; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

EID: 0036855861     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00127893-200211000-00002     Document Type: Review

References (105)

1. Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population. Eur J Pain. 1999;3:335-342.
2. Ragozzino MW, Melton LJ III, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61:310-316.
3. Kost RG, Straus SE. Postherpetic neuralgia: Pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32-42.
4. Helgason S, Petursson G, Gudmundsson S, et al. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: Prospective study with long term follow up. BMJ. 2000;321:794-796.
5. Lojeski E, Stevens RA. Postherpetic neuralgia in the cancer patient. Curr Rev Pain. 2000;4:219-226.
6. Livengood JM. The role of stress in the development of herpes zoster and postherpetic neuralgia. Curr Rev Pain. 2000;4:7-11.
7. Whitley RJ, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis. 1998;178(suppl 1):S71-S75.
8. Dworkin RH, Hartstein G, Rosner HL, et al. A high-risk method for studying psychosocial antecedents of chronic pain: The prospective investigation of herpes zoster. J Abnorm Psychol. 1992;101:200-205.
9. Whirley RJ, Lakeman F. Herpes simplex virus infections of the central nervous system: Therapeutic and diagnostic considerations. Clin Infect Dis. 1995;20:414-420.
10. Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996;22:341-347.
11. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996:67;241-251.
12. Nurmikko T, Bowsher D. Somatosensory findings in postherpetic neuralgia. J Neurol Neurosurg Psychiatry. 1990;53:135-141.
13. Rowbotham MC, Fields HL. Post-herpetic neuralgia: The relation of pain complaint, sensory disturbance, and skin temperature. Pain. 1989;39:129-144.
14. Rowbotham MC, Fields HL. The relationship of pain, allodynia and thermal sensation in post-herpetic neuralgia. Brain. 1996;119(pt 2):347-354.
15. Higa K, Dan K, Manabe H, et al. Factors influencing the duration of treatment of acute herpetic pain with sympathetic nerve block: Importance of seventy of herpes zoster assessed by the maximum antibody titers to varicella-zoster virus in otherwise healthy patients. Pain. 1988;32:147-157.
16. Higa K, Noda B, Manabe H, et al. T-lymphocyte subsets in otherwise healthy patients with herpes zoster and relationships to the duration of acute herpetic pain. Pain. 1992;51:111-118.
17. Glaser R, Kiecolt-Glaser JK. Stress-associated immune modulation: Relevance to viral infections and chronic fatigue syndrome. Am J Med. 1998;105:35S-42S.
18. Wildenhoff KE, Esmann V, Ipsen J, et al. Treatment of trigeminal and thoracic zoster with idoxuridine. Scand J Infect Dis. 1981;13:257-262.
19. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39:1546-1553.
20. Pilowsky I. Psychological aspects of post-herpetic neuralgia: Some clinical observations. Br J Med Psychol. 1977;50:283-288.
21. Rose MJ, Klenerman L, Atchison L, et al. An application of the fear avoidance model to three chronic pain problems. Behav Res Ther. 1992;30:359-365.
22. Engberg IB, Grondahl GB, Thibom K. Patients' experiences of herpes zoster and postherpetic neuralgia. J Adv Nurs. 1995;21:427-433.
23. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, et al. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 2000;342:635-645.
24. Watson CP, Watt VR, Chipman M, et al. The prognosis with postherpetic neuralgia. Pain. 1991;46:195-199.
25. Schon F, Mayer ML, Kelly JS. Pathogenesis of post-herpetic neuralgia. Lancet. 1987;2:366-368.
26. Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain. 2001;92:139-145.
27. Petersen KL, Fields HL, Brennum J, et al. Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain. 2000;88:125-133.
28. Baron R. Peripheral neuropathic pain: From mechanisms to symptoms. Clin J Pain. 2000;16(2 suppl):S12-S20.
29. Rowbotham MC, Petersen KL, Fields HL. Is postherpetic neuralgia more than one disorder? Pain Forum. 1998;7:231-237.
30. Pappagallo M, Oaklander AL, Quatrano-Piacentini AL, et al. Heterogenous patterns of sensory dysfunction in postherpetic neuralgia suggest multiple pathophysiologic mechanisms. Anesthesiology. 2000;92:691-698.
31. Bonica JJ. History of pain concepts and therapies. In: Bonica JJ, ed. The Management of Pain. Philadelphia: Lea & Feabiger; 1990:2-18.
32. Watson CP. The treatment of neuropathic pain: Antidepressants and opioids. Clin J Pain. 2000;16(2 suppl):S49-S55.
33. Kanazi GE, Johnson RW, Dworkin RH. Treatment of postherpetic neuralgia: An update. Drugs. 2000;59:1113-1126.
34. Collins SL, Moore RA, McQuay HJ, et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: A quantitative systematic review. J Pain Symptom Manage. 2000;20:449-458.
35. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain. 1999;83:389-400.
36. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain. 2001;94:215-224.
37. Gobel H, Stadler T. [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine]. Drugs. 1997;53(suppl 2):34-39.
38. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842-1846.
39. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988;33:11-23.
40. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837-1841.
41. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: A randomized placebo-controlled trial. Neurology. In press.
42. Eide PK, Jorum E, Stubhaug A, et al. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placebo. Pain. 1994;58:347-354.
43. Eide K, Stubhaug A, Oye I, et al. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain. 1995;61:221-228.
44. Hoffmann V, Coppejans H, Vercauteren M, et al. Successful treatment of postherpetic neuralgia with oral ketamine. Clin J Pain. 1994;10:240-242.
45. Klepstad P, Borchgrevink PC. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand. 1997;41:422-426.
46. Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48:1212-1218.
47. Eisenberg E, Kleiser A, Dortort A, et al. The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: A double-blind, placebo-controlled study. Eur J Pain. 1998;2:321-327.
48. Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. J Pain Symptom Manage. 1999;17:429-433.
49. Ichimata M, Ikebe H, Yoshitake S, et al. Analgesic effects of flecainide on postherpetic neuralgia. Int J Clin Pharmacol Res. 2001;21:15-19.
50. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol. 1995;37:246-253.
51. Attal N, Brasseur L, Chauvin M, et al. Effects of single and repeated applications of a eutectic mixture of local anaesthetics (EMLA) cream on spontaneous and evoked pain in post-herpetic neuralgia. Pain. 1999;81(1-2):203-209.
52. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: Double-blind controlled study of a new treatment method for postherpetic neuralgia. Pain. 1996;65:39-44.
53. Rumsfield JA, West DP. Topical capsaicin in dermatologic and peripheral pain disorders. DICP. 1991;25:381-387.
54. Fusco BM, Giacovazzo M. Peppers and pain: The promise of capsaicin. Drugs. 1997;53:909-914.
55. Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21(2 pt 1):265-270.
56. Bucci FA Jr, Gabriels CF, Krohel GB., Successful treatment of postherpetic neuralgia with capsaicin. Am J Ophtalmol. 1988;106:758-759.
57. Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15:510-526.
58. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med. 2000;343:1514-1519.
59. Kikuchi A, Kotani N, Sato T, et al. A comparative therapeutic evaluation of intrathecal versus epidural methylprednisolone for long-term analgesia in patients with intractable postherpetic neuralgia. Reg Anesth Pain Med. 1999;24:287-293.
60. Nelson DA, Landau WM. Intrathecal methylprednisolone for postherpetic neuralgia. N Engl J Med. 2001;344:1019-1012.
61. Watson CP. A new treatment for postherpetic neuralgia. N Engl J Med. 2000;343:1563-1565.
62. Nelson DA. Intraspinal therapy using methylprednisolone acetate: Twenty-three years of clinical controversy. Spine. 1993;18:278-286.
63. Ahn HJ, Lim HK, Lee YB, et al. The effects of famciclovir and epidural block in the treatment of herpes zoster. J Dermatol. 2001;28:208-216.
64. Hwang SM, Kang YC, Lee YB, et al. The effects of epidural blockade on the acute pain in herpes zoster. Arch Dermatol. 1999;135:1359-1364.
65. Manabe H, Dan K, Higa K. Continuous epidural infusion of local anesthetics and shorter duration of acute zoster-associated pain. Clin J Pain. 1995;11:220-228.
66. Perkins HM, Hanlon PR. Epidural injection of local anesthetic and steroids for relief of pain secondary to herpes zoster. Arch Surg. 1978;113:253-254.
67. Kang FC, Chang PJ, Chen HP, et al. Patient-controlled epidural analgesia for postherpetic neuralgia in an HIV-infected patient as a therapeutic ambulatory modality. Acta Anaesthesiol Sin. 1998;36:235-239.
68. Watt JW, Wiles JR, Bowsher DR. Epidural morphine for postherpetic neuralgia. Anaesthesia. 1996;51:647-651.
69. Winnie AP, Hartwell PW. Relationship between time of treatment of acute herpes zoster with sympathetic blockade and prevention of post-herpetic neuralgia: Clinical support for a new theory of the mechanism by which sympathetic blockade provides therapeutic benefit. Reg Anesth. 1993;18:277-282.
70. Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain. 2000;87:121-129.
71. Reiestad F, Kvalheim L, McIlvaine WB. Pleural analgesia for the treatment of acute severe thoracic herpes zoster. Reg Anesth. 1989;14:244-246.
72. Reiestad F, McIlvaine WB, Barnes M, et al. Interpleural analgesia in the treatment of severe thoracic postherpetic neuralgia. Reg Anesth. 1990;15:113-117.
73. Jones MJ, Murrin KR. Intercostal block with cryotherapy. Ann R Coll Surg Engl. 1987;69:261-262.
74. Bhargava R, Bhargava S, Haldia KN, et al. Jaipur block in postherpetic neuralgia. Int J Dermatol. 1998;37:465-468.
75. Carroll D, Moore RA, McQuay HJ, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. Cochrane Database Syst Rev. 2001;3:CD003222.
76. Spiegelmann R, Friedman WA. Spinal cord stimulation: A contemporary series. Neurosurgery. 1991;28:65-70.
77. Kumar K, Toth C, Nath RK. Spinal cord stimulation for chronic pain in peripheral neuropathy. Surg Neurol. 1996;46:363-369.
78. Young RF. Electrical stimulation of the trigeminal nerve root for the treatment of chronic facial pain. J Neurosurg. 1995;83:72-78.
79. Taub E, Munz M, Tasker RR. Chronic electrical stimulation of the gasserian ganglion for the relief of pain in a series of 34 patients. J Neurosurg. 1997;86:197-202.
80. Kumar K, Toth C, Nath RK. Deep brain stimulation for intractable pain: A 15-year experience. Neurosurgery. 1997;40:736-746.
81. Cluff RS, Rowbotham MC. Pain caused by herpes zoster infection. Neurol Clin. 1998;16:813-832.
82. Loeser JD. Dorsal rhizotomy for the relief of chronic pain. J Neurosurg. 1972;36:745-750.
83. Onofrio BM, Campa HK. Evaluation of rhizotomy: Review of 12 years' experience. J Neurosurg. 1972;36:751-755.
84. Smith FP. Trans-spinal ganglionectomy for relief of intercostal pain. J Neurosurg. 1970;32:574-577.
85. Bullard DE, Nashold BS Jr. The caudalis DREZ for facial pain. Stereotact Funct Neurosurg. 1997;68(1-4 pt 1):168-174.
86. Gorecki JP, Nashold BS. The Duke experience with the nucleus caudalis DREZ operation. Acta Neurochir Suppl (Wien). 1995;64:128-131.
87. Rath SA, Braun V, Soliman N, et al. Results of DREZ coagulations for pain related to plexus lesions, spinal cord injuries and postherpetic neuralgia. Acta Neurochir (Wien). 1996;138:364-369.
88. Rath SA, Seitz K, Soliman N, et al. DREZ coagulations for deafferentation pain related to spinal and peripheral nerve lesions: Indication and results of 79 consecutive procedures. Stereotact Funct Neurosurg. 1997;68(1-4 pt 1):161-167.
89. Urgosik D, Vymazal J, Vladyka V, et al. Treatment of postherpetic trigeminal neuralgia with the gamma knife. J Neurosurg. 2000;93 (suppl 3):165-168.
90. Urgosik D, Vymazal J, Vladyka V, et al. Gamma knife treatment of trigeminal neuralgia: Clinical and electrophysiological study. Stereotact Funct Neurosurg. 1998;70(suppl 1):200-209.
91. Haythornthwaite JA, Benrud-Larson LM. Psychological assessment and treatment of patients with neuropathic pain. Curr Pain Headache Rep. 2001;5:124-129.
92. Lewith GT, Field J, Machin D. Acupuncture compared with placebo in post-herpetic pain. Pain. 1983;17:361-368.
93. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: A randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 1997;13:327-331.
94. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia: A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995;123:89-96.
95. Dworkin RH, Boon RJ, Griffin DR, et al. Postherpetic neuralgia: Impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis. 1998;178(suppl 1):S76-S80.
96. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: An overview of clinical trials with acyclovir. Scand J Infect Dis Suppl. 1991;80:62-68.
97. Boon RJ, PJ, Griffin DR. Efficacy of famciclovir in the treatment of herpes zoster: Reduction of pain associated with zoster. Neurology. 1995;45(12 suppl 8):S76-S77.
98. Alper BS, Lewis PR. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? J Fam Pract. 2000;49:255-264.
99. Ahmed HE, Craig WF, White PF, et al. Percutaneous electrical nerve stimulation: An alternative to antiviral drugs for acute herpes zoster. Anesth Analg. 1998;87:911-914.
100. Johnson R. Herpes zoster: Predicting and minimizing the impact of post-herpetic neuralgia. J Antimicrob Chemother. 2001;47(suppl T1):1-8.
101. Levin MJ, Barber D, Goldblatt E, et al. Use of a live attenuated varicefla vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect. J Infect Dis. 1998;178(suppl 1):S109-S112.
102. Takahashi M, Kamiya H, Asano Y, et al. Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction. Arch Virol Suppl. 2001;17:161-172.
103. Trannoy E, Berger R, Hollander G, et al. Vaccination of inununocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: A randomized, controlled, dose-response trial. Vaccine. 2000;18:1700-1706.
104. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology. 1995;45(12 suppl 8):S41-S46.
105. Cohen JI, Brunell PA, Straus SE. et al. Recent advances in varicellazoster virus infection. Ann Intern Med. 1999;130:922-932.